Lisheng Pharma grants restricted stock under 2024 incentive plan

Tianjin Lisheng Pharmaceutical (SZSE:002393) announced the first grant of restricted stock under its 2024 incentive plan. On February 12, 2025, the company granted 5.77 million shares at a price of 10.59 yuan per share to 147 eligible employees. The grant aims to align employee interests with company performance. The stock comes from repurchased A-shares. Vesting occurs over three years, contingent on both company and individual performance metrics, including earnings per share growth, revenue growth, and inventory turnover rates. The plan's overall goal is to bolster long-term shareholder value and employee retention.